Ascelia Pharma (One pager): On track into the final stretch ahead of July 3 PDUFA

We have made only minor adjustments to our Ascelia Pharma one-pager following the Q1 2026 results. With less than two months remaining until the July 3 PDUFA date, the report itself contained limited new information, and the investment case stays largely intact.

The headline takeaway from Q1 is that the FDA review remains on track. On the conference call, management was explicit that the agency's review of the Orviglance NDA is progressing according to plan and that dialogue has been smooth so far. Importantly, CSO Andreas Norlin noted that questions received from the FDA have been across the board - efficacy, safety, CMC, and nonclinical - which is exactly what is expected at this stage, with no indication of surprising or problematic areas of focus. The review is now entering the standard label-discussion phase. This is a meaningful incremental positive: while the binary nature of FDA approval cannot be eliminated, the absence of red flags through this final stretch of the 10-month review still supports the case that Orviglance is on track for approval on July 3.

On the partnering front, management reiterated that discussions continue to advance with multiple potential partners showing strong strategic interest. The likelihood of a deal being signed ahead of the PDUFA decision appears to have declined relative to our previous expectations, increasing the case-specific risk slightly. CEO Magnus Corfitzen noted on the call that the deal could come either before or after approval, with partners now more focused on commercial preparations than on the scientific diligence, which the FDA is effectively doing on their behalf. While a post-approval deal would lower partner risk, it would also remove a near-term value-validation catalyst. However, as the main value driver in our model is the royalty stream rather than upfront payments, and as the April capital raise has covered the funding gap that a delayed deal would have created, the overall picture and our valuation framework remain unchanged. Securing a deal after approval could also bring upside to terms relative to what we currently model in our PoS assumptions.

We have made small adjustments to the model, including pushing the commercial launch into 2027 to reflect the time needed for a partner to onboard and ramp up post-approval. The base case PoS remains around 37%, materially below the ~91% historical benchmark for Phase III-complete candidates with strong data. The gap suggests the market continues to price in slower commercialization, lower peak market share, or residual dilution risk - despite the runway extension reducing funding concerns. FDA approval and a partnership agreement remain the two key catalysts to narrow this discount.

The core case is intact: Orviglance is the first and only gadolinium-free liver MRI contrast agent for patients with severe kidney impairment, supported by Orphan Drug Designation, no current competition, and an USD 800m global addressable market. Both of the two high-value catalysts expected in 2026 - FDA approval/launch and a partnership agreement - are now fully funded by the cash runway extending into 2027.

Key risks include the inherent uncertainty of FDA approval, reliance on a single primary pipeline candidate, the challenge of securing a strong partner on favorable terms (with the timing now potentially shifting to post-approval), and uncertainty around commercial adoption and reimbursement for a first-in-class diagnostic product.

For further inside watch management presentation of the Q1 2026 results here: 

Ascelia - Q1 2026 Event

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. / Michael Friis Jørgensen, 10:00, 15/05/2026